Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Judith A. Seidel, Atsushi Otsuka, Kenji Kabashima
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 1188

Showing 1-25 of 1188 citing articles:

Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1313
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 1020
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Luca Falzone, Salvatore Salomone, Massimo Libra
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 788
Immune Checkpoint Inhibitors in Cancer Therapy
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, et al.
Current Oncology (2022) Vol. 29, Iss. 5, pp. 3044-3060
Open Access | Times Cited: 729
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
Yucai Wang, Shouhao Zhou, Fang Yang, et al.
JAMA Oncology (2019) Vol. 5, Iss. 7, pp. 1008-1008
Open Access | Times Cited: 681
In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles
Yeteng Zhong, Zhuoran Ma, Feifei Wang, et al.
Nature Biotechnology (2019) Vol. 37, Iss. 11, pp. 1322-1331
Open Access | Times Cited: 492
Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 468
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wei Wu, Jessica Klockow, Michael Zhang, et al.
Pharmacological Research (2021) Vol. 171, pp. 105780-105780
Open Access | Times Cited: 454
Next generation of immune checkpoint inhibitors and beyond
Julian A. Marin‐Acevedo, ErinMarie O. Kimbrough, Yanyan Lou
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 447
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 3, pp. 230-241
Open Access | Times Cited: 411
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Selena Viganó, Dimitrios Alatzoglou, Melita Irving, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 352
Colorectal Cancer Immunotherapy: Options and Strategies
Nor Adzimah Johdi, Nur Fazilah Sukor
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 348
Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer
Helena Gavilán, Sahitya Kumar Avugadda, Tamara Fernández, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 20, pp. 11614-11667
Open Access | Times Cited: 329
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Kyoko Oura, Asahiro Morishita, Joji Tani, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5801-5801
Open Access | Times Cited: 313
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Jinhua Liu, Zichao Chen, Yaqun Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 309
NK Cell-Based Immune Checkpoint Inhibition
Muhammad Khan, Sumbal Arooj, Hua Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 277
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Christopher Tay, Atsushi Tanaka, Shimon Sakaguchi
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 450-465
Open Access | Times Cited: 259
The pharmacology and therapeutic applications of monoclonal antibodies
Sofia Castelli, Paul McGonigle, Pamela J. Hornby
Pharmacology Research & Perspectives (2019) Vol. 7, Iss. 6
Open Access | Times Cited: 253
Gut microbiome, big data and machine learning to promote precision medicine for cancer
Giovanni Cammarota, Gianluca Ianiro, Anna M. Ahern, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 10, pp. 635-648
Closed Access | Times Cited: 242
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto, Francheska Caminero, Lindsay Cash, et al.
Translational Oncology (2020) Vol. 13, Iss. 3, pp. 100738-100738
Open Access | Times Cited: 234
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
Ingrid Lilienthal, Nikolas Herold
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6885-6885
Open Access | Times Cited: 227
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Reem Saleh, Eyad Elkord
Seminars in Cancer Biology (2019) Vol. 65, pp. 13-27
Closed Access | Times Cited: 222
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair, Heather J. Bax, Silvia Mele, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 220
A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
Qianqian Ni, Fuwu Zhang, Yijing Liu, et al.
Science Advances (2020) Vol. 6, Iss. 12
Open Access | Times Cited: 215
ESR1 mutations in breast cancer
Derek Dustin, Guowei Gu, Suzanne A.W. Fuqua
Cancer (2019) Vol. 125, Iss. 21, pp. 3714-3728
Open Access | Times Cited: 214
Page 1 - Next Page

Scroll to top